IL17A and central nervous system cancer: The isoquinoline derivative ISO‐1 exemplifies this category, demonstrating dual anti‐neoplastic and immunomodulatory properties through competitive MIF binding, effectively suppressing CD74‐mediated signalling, reducing pro‐inflammatory cytokine secretion (TNF, IFN‐γ, IL‐4, IL‐17), and inhibiting glioma proliferation [24].